Firebrick Pharma (ASX:FRE) Interest Expense : A$-0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Firebrick Pharma's interest expense for the six months ended in Dec. 2024 was A$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Firebrick Pharma's Operating Income for the six months ended in Dec. 2024 was A$ -1.62 Mil. Firebrick Pharma's Interest Expense for the six months ended in Dec. 2024 was A$ 0.00 Mil. Firebrick Pharma has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Firebrick Pharma Interest Expense Historical Data

The historical data trend for Firebrick Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Interest Expense Chart

Firebrick Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Interest Expense

Firebrick Pharma Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Interest Expense	Get a 7-Day Free Trial			-	-	-	-	-

Firebrick Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.00 Mil.

Firebrick Pharma (ASX:FRE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Firebrick Pharma's Interest Expense for the six months ended in Dec. 2024 was A$0.00 Mil. Its Operating Income for the six months ended in Dec. 2024 was A$-1.62 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2024 was A$0.00 Mil.

Firebrick Pharma's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Firebrick Pharma had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Firebrick Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000

Website

https://www.firebrickpharma.com

Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines